Scotland decision helps Opdivo in UK market access picture
NHS initially denied late writer immunotherapy.
Latest approval for Opdivo good news, but won’t make up for lung cancer setback
NHS England will be able to control cost impact of NICE decisions more directly.
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Despite Keytruda’s overwhelming victory, it’s not over yet in NSCLC